Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel plus tissue brachytherapy for locally recurrent cervical squamous cell carcinoma after prior chemoradiotherapy
ChiCTR2000034101Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Inner Mongolia Medical University
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paclitaxel in Cervical Cancer (CC) and cervical squamous cell carcinoma (CSCC), sponsored by Affiliated Hospital of Inner Mongolia Medical University. Primary endpoint: overall response rate. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
paclitaxel
03
Conditions
Cervical Cancer (CC)cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on ChiCTR2000034101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034101.